On Friday, Invivyd Inc. IVVD introduced that new in vitro neutralization information present continued neutralizing exercise of Pemgarda (pemivibart) and pipeline candidate VYD2311 towards dominant SARS-CoV-2 variant XEC.
The inventory is buying and selling with a powerful session quantity of 12.3 million, in comparison with a median quantity of 757.02k as per information from Benzinga Professional.
As anticipated, the info are largely in keeping with these beforehand reported for KP.3.1.1, based mostly on the structural biology of pemivibart and VYD2311.
The Facilities for Illness Management (CDC) estimates that XEC and KP.3.1.1 accounted for an mixture 69% of U.S. circulating variants of SARS-CoV-2 for the 2 weeks ended December 21, 2024.
Invivyd generated these new information as a part of its ongoing industrial virology effort. It leverages a third-party pseudoviral system that routinely checks genuine Invivyd-produced pemivibart and is supported by in depth structure-based and proprietary analytics.
Invivyd has confirmed optimistic Pemgarda neutralization exercise towards over 75% of presently circulating U.S. variants and all prior variants examined so far.
Additional, the corporate estimates that each scientific variant reported within the CDC COVID Tracker because the Omicron BA.1 lineage has been prone to pemivibart, even when untested, because of the constant structural integrity of the pemivibart epitope.
Subsequently, Invivyd doesn’t anticipate any significant change to pemivibart neutralization exercise, apart from anticipated regular quantitative variation in assay output, for the foreseeable future if the epitope pemivibart targets stay structurally intact, because it has since Omicron BA.1.
In November, Invivyd introduced {that a} manuscript preprint conveying information from the CANOPY Section 3 scientific trial of pemivibart for the pre-exposure prophylaxis of COVID-19, together with long-term safety proven versus latest JN.1 sublineages at low residual titers, was uploaded to MedRxiv.
Value Motion: IVVD inventory is down 5.5% at $0.4357 eventually verify Friday.
Learn Subsequent:
Photograph by way of Shutterstock.
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
